ArticleAmerican journal of translational research2024
Triglyceride-glucose index in patients with non-functioning adrenal incidentaloma, cortisol-secreting adrenal incidentaloma and healthy controls.
Article in American journal of translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Study of Adrenal Incidentaloma-Related Hormonal Assays After First Integration of the Diagnosis Within Primary Healthcare.Diseases (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCushing's syndrome increases the risk of cardiovascular disease. The triglyceride-glucose (TyG) index has been linked to an increased risk of cardiometabolic disorders. Whether patients with non-functioning adrenal incidentaloma (NFAI) or cortisol-secreting adrenal incidentaloma (CSAI) have altered TyG index is unknown. Therefore, we aimed to investigate the TyG index between adrenal incidentaloma patients and controls. MATERIALS AND
methodsThis cross-sectional study retrospectively included patients with NFAI, CSAI and healthy controls admitted to a tertiary endocrinology service. Subjects receiving hormone replacement, or having cancer, diabetes mellitus, alcoholism, psychiatric disorders, hepatic and/or renal insufficiency or morbid obesity were excluded. TyG index was calculated using the following formula: (Ln [fasting triglyceride (mg/dL) × fasting glucose (mg/dL)]/2). The primary endpoint was the difference in TyG index between patients with NFAI, CSAI and healthy controls.
resultsA total of 142 patients with incidentaloma [NFAI, n=95, age: 60.9±10.6 years, women: 75.8%; CSAI, n=47, age: 59.6±13.7 years, women: 63.8%] and 116 age and sex matched healthy controls (age: 59.8±13.4 years, women: 76.7%) were evaluated. Compared with healthy controls, patients with overall incidentaloma, NFAI and CSAI had increased TyG index (6.39±1.87 vs. 8.85±0.52, 8.76±0.25, and 8.81±0.51, respectively, P<0.001 for all). There was no difference in TyG index between patients with NFAI and CSAI (8.76±0.25 vs. 8.81±0.51), and with possible autonomous cortisol secretion, autonomous cortisol secretion and Cushing's syndrome (8.80±0.54, 8.86±0.52 and 9.31±0.37).
conclusionThis study showed increased TyG index in patients with NFAI or CSAI, emphasizing the importance of cardiometabolic risk assessment in patients with adrenal incidentaloma even if it is non-functioning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.